PLEGRIDY

Peak

peginterferon beta-1a

Biogen

BLAINJECTIONINJECTABLE

Approved

Aug 2014

Lifecycle

Peak

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

PLEGRIDY (peginterferon beta-1a) by Biogen is 12. Approved for relapsing multiple sclerosis, multiple sclerosis. First approved in 2014.

Drug data last refreshed 21h ago

Mechanism of Action

12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. 12.2 Pharmacodynamics There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. 12.3 Pharmacokinetics After single-dose or…

Worked on PLEGRIDY at Biogen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (14)

NCT04655222N/ACompleted

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Started Apr 2021

470 enrolled

Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting

NCT03958877Phase 3Active Not Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Started Oct 2019

152 enrolled

Multiple Sclerosis, Relapsing-Remitting

NCT03870763Phase 3Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Started Mar 2019

11 enrolled

Multiple Sclerosis, Relapsing-Remitting

NCT05242133Phase 3Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Started Dec 2017

168 enrolled

Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03091569Phase 4Completed

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Started Mar 2017

23 enrolled

Relapsing-Remitting Multiple Sclerosis

PLEGRIDY

Mechanism of Action

Indications (2)

Clinical Trials (14)